# EDGAR Filing Document

**Accession Number:** 0001536196
**File Stem:** 0000000000-23-001195
**Filing Date:** 2023-2
**Character Count:** 3371
**Document Hash:** 74b2ae20c35513dbcee600f43cc6fc68
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001195.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0000000000-23-001195

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230206

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Can-Fite BioPharma Ltd.
- **CENTRAL INDEX KEY:** 0001536196
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 10 BAREKET STREET, KIRYAT MATALON
- **STREET 2:** P.O. BOX 7537
- **CITY:** PETACH TIKVA
- **STATE:** L3
- **ZIP:** 4951778
- **BUSINESS PHONE:** 972 39241114

**MAIL ADDRESS:**
- **STREET 1:** 10 BAREKET STREET, KIRYAT MATALON
- **STREET 2:** P.O. BOX 7537
- **CITY:** PETACH TIKVA
- **STATE:** L3
- **ZIP:** 4951778

## Text-Extract

```

United States securities and exchange commission logo

                          February 6, 2023

       Pnina Fishman, Ph.D.
       Chief Executive Officer
       Can-Fite BioPharma Ltd.
       10 Bareket Street
       Kiryat Matalon
       P.O. Box 7537
       Petach-Tikva
       4951778, Israel

                                                        Re: Can-Fite BioPharma
Ltd.
                                                            Registration
Statement on Form F-1
                                                            Filed January 31,
2023
                                                            File No. 333-269485

       Dear Pnina Fishman:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jason
Drory at 202-551-8342 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Gary M. Emmanuel

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 6, 2023

Pnina Fishman, Ph.D.
Chief Executive Officer
Can-Fite BioPharma Ltd.
10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petach-Tikva
4951778, Israel

Re: Can-Fite BioPharma Ltd.
Registration Statement on Form F-1
Filed January 31, 2023
File No. 333-269485

Dear Pnina Fishman:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Gary M. Emmanuel